The role of neoadjuvant chemoradiotherapy in multimodality treatment of esophageal or gastroesophageal junction cancer

被引：0
作者：
Klevebro, Fredrik [1 ,2 ]
Nilsson, Magnus
机构：
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Surg, Stockholm, Sweden
[2] Karolinska Univ Hosp, Ctr Upper Gastrointestinal Canc, Stockholm, Sweden
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷 / 01期
关键词：
PHASE-III TRIAL; CHEMOTHERAPY; ADENOCARCINOMA; MULTICENTER;
D O I：
10.21037/jtd.2017.11.139
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：E87 / E89
页数：3
相关论文
共 9 条
  • [1] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
    Al-Batran, Salah-Eddin
    Hofheinz, Ralf D.
    Pauligk, Claudia
    Kopp, Hans-Georg
    Haag, Georg Martin
    Luley, Kim Barbara
    Meiler, Johannes
    Homann, Nils
    Lorenzen, Sylvie
    Schmalenberg, Harald
    Probst, Stephan
    Koenigsmann, Michael
    Egger, Matthias
    Prasnikar, Nicole
    Caca, Karel
    Trojan, Joerg
    Martens, Uwe M.
    Block, Andreas
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Clemens, Michael
    Illerhaus, Gerald
    Zirlik, Katja
    Behringer, Dirk M.
    Schmiegel, Wolff
    Pohl, Michael
    Heike, Michael
    Ronellenfitsch, Ulrich
    Schuler, Martin
    Bechstein, Wolf O.
    Koenigsrainer, Alfred
    Gaiser, Timo
    Schirmacher, Peter
    Hozaeel, Wael
    Reichart, Alexander
    Goetze, Thorsten O.
    Sievert, Mark
    Jaeger, Elke
    Moenig, Stefan
    Tannapfel, Andrea
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1697 - 1708
  • [2] Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial
    Burmeister, Bryan H.
    Thomas, Janine M.
    Burmeister, Elizabeth A.
    Walpole, Euan T.
    Harvey, Jennifer A.
    Thomson, Damien B.
    Barbour, Andrew P.
    Gotley, David C.
    Smithers, B. Mark
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (03) : 354 - 360
  • [3] ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
    Hoeppner, Jens
    Lordick, Florian
    Brunner, Thomas
    Glatz, Torben
    Bronsert, Peter
    Roethling, Nadine
    Schmoor, Claudia
    Lorenz, Dietmar
    Ell, Christian
    Hopt, Ulrich T.
    Siewert, J. Ruediger
    [J]. BMC CANCER, 2016, 16
  • [4] ICORG 10-14: Neo-AEGIS: A randomized clinical trial of neoadjuvant and adjuvant chemotherapy (modified MAGIC regimen) versus neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the esophagus and esophagogastric junction.
    Keegan, Niamh
    Keane, Fionnuala
    Cuffe, Sinead
    Cunningham, Moya
    Ravi, Narayanasamy
    Lee, Geraldine
    Kennedy, M. John
    Grogan, William
    O'Neill, Brian
    Power, Derek G.
    Leonard, Gregory
    Keane, Maccon M.
    Small, Cormac
    Parker, Imelda
    Moulton, Brian
    O'Reilly, Seamus
    Reynolds, John Vincent
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry
    Klevebro, F.
    Lindblad, M.
    Johansson, J.
    Lundell, L.
    Nilsson, M.
    [J]. BRITISH JOURNAL OF SURGERY, 2016, 103 (13) : 1864 - 1873
  • [6] A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction
    Klevebro, F.
    von Dobeln, G. Alexandersson
    Wang, N.
    Johnsen, G.
    Jacobsen, A. -B.
    Friesland, S.
    Hatlevoll, I.
    Glenjen, N. I.
    Lind, P.
    Tsai, J. A.
    Lundell, L.
    Nilsson, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 660 - 667
  • [7] TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
    Leong, Trevor
    Smithers, B. Mark
    Michael, Michael
    Gebski, Val
    Boussioutas, Alex
    Miller, Danielle
    Simes, John
    Zalcberg, John
    Haustermans, Karin
    Lordick, Florian
    Schuhmacher, Christoph
    Swallow, Carol
    Darling, Gail
    Wong, Rebecca
    [J]. BMC CANCER, 2015, 15
  • [8] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
    Noordman, Bo Jan
    Shapiro, Joel
    Spaander, Manon C. W.
    Krishnadath, Kausilia K.
    van Laarhoven, Hanneke W. M.
    Henegouwen, Mark I. van Berge
    Nieuwenhuijzen, Grard A. P.
    van Hillegersberg, Richard
    Sosef, Meindert N.
    Steyerberg, Ewout W.
    Wijnhoven, Bas P. L.
    van Lanschot, J. Jan B.
    [J]. JMIR RESEARCH PROTOCOLS, 2015, 4 (02):
  • [9] Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
    Stahl, Michael
    Walz, Martin K.
    Stuschke, Martin
    Lehmann, Nils
    Meyer, Hans-Joachim
    Riera-Knorrenschild, Jorge
    Langer, Peter
    Engenhart-Cabillic, Rita
    Bitzer, Michael
    Koenigsrainer, Alfred
    Budach, Wilfried
    Wilke, Hansjochen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 851 - 856
1